Blood Coral Polysaccharide Helps Prevent D-Gal/LPS-Induced Acute Liver Failure in Mice
Chong Li,Shu Lai,Ruokun Yi,Xianrong Zhou,Xin Zhao,Qiang Li
DOI: https://doi.org/10.2147/JIR.S369176
IF: 4.5
2022-08-09
Journal of Inflammation Research
Abstract:Chong Li, 1, 2, &ast Shu Lai, 3, &ast Ruokun Yi, 1 Xianrong Zhou, 1, 2 Xin Zhao, 1 Qiang Li 4 1 Collaborative Innovation Center for Child Nutrition and Health Development, Chongqing Engineering Research Center of Functional Food, Chongqing Engineering Laboratory for Research and Development of Functional Food, Chongqing University of Education, Chongqing, People's Republic of China; 2 Department of Food and Nutrition, College of Medical and Life Science, Silla University, Busan, Republic of Korea; 3 Department of Pharmacology, Jiulongpo District People's Hospital of Chongqing, Chongqing, People's Republic of China; 4 Department of Emergency, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xin Zhao; Qiang Li, Email ; Objective: The liver protection of blood coral polysaccharide (BCP) was investigated. Materials and Methods: We evaluated the effect of BCP on liver pathology, liver function, oxidation and inflammation-related indicators of D-Gal/LPS-induced acute liver failure (ALF) mice in vivo. Results: Liver index and liver pathology observation in mice showed that BCP could inhibit liver tissue swelling and hemorrhage, hepatocyte damage, and inflammatory infiltration in ALF. Serum liver function results showed that BCP effectively inhibits the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), total bilirubin (TBil), alkaline phosphatase (AKP), myeloperoxidase (MPO). High dose-blood coral polysaccharide (H-BCP) was better than silymarin. Serum antioxidant and immune results showed that BCP increased the levels of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and glutathione peroxidase (GSH-Px), and inhibited the levels of malondialdehyde (MDA) and nitric oxide (NO). Also, BCP increased immunoglobulins G (IgG) and A (IgA) levels, thereby enhancing humoral immunity. Liver anti-inflammatory ELISA results showed that BCP reduced the levels of interleukin (IL)-6, IL-1β, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, and enhanced the level of anti-inflammatory factor IL-10. H-BCP was the most effective treatment. Real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR) of liver tissues confirmed that BCP increases the relative expression levels of antioxidant and anti-inflammatory-related cuprozinc superoxide dismutase (Cu/Zn-SOD, SOD1), manganese superoxide dismutase (Mn-SOD, SOD2), CAT, GSH, GSH-Px, and IL-10. In contrast, it inhibits inflammation-related genes IL-6, IL-1β, IL-17, TNF-α, IFN-γ, inducible nitric oxide synthase (iNOS, NOS2), and cyclooxygenase (COX)-2. In addition, BCP also inhibits the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and enhance B-cell inhibitor-α (IκB-α) gene relative expression in the liver, which may be related to NF-κB pathway inhibition. Conclusion: BCP prevents D-Gal/LPS-induced ALF in mice, and its effect is concentration dependent. Keywords: blood coral polysaccharide, acute liver failure, antioxidant, anti-inflammatory, immunomodulatory Massive hepatocyte necrosis and severe liver dysfunction cause acute liver failure (ALF), often accompanied by hepatic encephalopathy. ALF is most common in young and middle-aged patients with liver disease. The clinical course is progressive multiple organ failure, with rapid onset, poor prognosis, and high mortality. There are no specific treatments, and most of them focus on maintaining the patient's vital functions, expecting liver function recovery, or liver transplantation. Defining ALF pathogenesis and finding effective treatment methods are currently the focus of researchers. 1 The combined D-galactose/Lipopolysaccharide (D-Gal/LPS) ALF induction model is simple to operate and has good reproducibility, making it the preferred ALF animal model. High levels of D-Gal are converted to aldose and hydroperoxides catalyzed by galactose oxidase in the liver, generating reactive oxygen species (ROS). 2 In addition, advanced glycation end products (AGEs) formed by the D-Gal reaction in vivo also exacerbate the oxidation process. 3 LPS is a pathogen-associated molecular pattern (PAMP), which mediates the innate immune response and induces inflammatory mediators by activating mononuclear phagocytic system (MPS) release and eventually developing ALF. 4 Most rodents are naturally resistant to LPS, so D-Gal sensitization combined with low-dose LPS is often used to establish an ALF animal model. D-Gal increases mice -Abstract Truncated-
immunology